Trial Profile
A Phase 1 Study of Milademetan in Combination With Quizartinib in Subjects With FLT3-ITD Mutant Acute Myeloid Leukemia That Are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Milademetan (Primary) ; Quizartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 14 Dec 2021 Results assessing the proteomic profiles of FLT3-ITD AML patients treated with MDM2i (Milademetan) plus FLT3i (Quizartinib) (NCT03552029) and interrogate the association between proteomic landscape and therapy response, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 14 May 2021 Status changed from recruiting to discontinued.
- 13 Feb 2020 Planned End Date changed from 15 Oct 2021 to 1 Nov 2023.